Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.32 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NKTR 1.32 0.00(0.00%)
Will NKTR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
Other News for NKTR
Biolojic Design: Nektar exercises license option to develop agonistic antibody
Sweet Nektar?
NKTR, VERU and EGIO among mid-day movers
12 Health Care Stocks Moving In Thursday's Intraday Session
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test